Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 4 | 2008 | 73 | 1.020 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2008 | 176 | 0.950 |
Why?
|
| Biomedical Research | 2 | 2023 | 371 | 0.830 |
Why?
|
| Zirconium | 3 | 2016 | 8 | 0.780 |
Why?
|
| Education, Graduate | 2 | 2015 | 27 | 0.580 |
Why?
|
| Ganglia, Spinal | 2 | 2017 | 36 | 0.570 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 30 | 0.550 |
Why?
|
| Elapid Venoms | 1 | 2015 | 16 | 0.540 |
Why?
|
| Drug Carriers | 2 | 2016 | 121 | 0.540 |
Why?
|
| Doxorubicin | 1 | 2016 | 80 | 0.540 |
Why?
|
| Career Choice | 2 | 2015 | 44 | 0.470 |
Why?
|
| Documentation | 1 | 2012 | 15 | 0.450 |
Why?
|
| Physiology | 1 | 2012 | 14 | 0.440 |
Why?
|
| Career Mobility | 1 | 2012 | 24 | 0.440 |
Why?
|
| Nanoparticles | 1 | 2016 | 294 | 0.410 |
Why?
|
| Mentors | 3 | 2023 | 111 | 0.400 |
Why?
|
| Apoptosis | 1 | 2016 | 1317 | 0.330 |
Why?
|
| Neurons | 1 | 2015 | 1130 | 0.320 |
Why?
|
| Environment | 1 | 2008 | 130 | 0.300 |
Why?
|
| Papillomaviridae | 2 | 2005 | 125 | 0.290 |
Why?
|
| DNA, Viral | 2 | 2005 | 295 | 0.280 |
Why?
|
| Neoplasms | 1 | 2016 | 1033 | 0.280 |
Why?
|
| Trans-Activators | 1 | 2005 | 167 | 0.250 |
Why?
|
| Intercalating Agents | 2 | 2013 | 12 | 0.220 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 522 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 316 | 0.200 |
Why?
|
| Humans | 12 | 2023 | 34853 | 0.180 |
Why?
|
| Echinococcosis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2017 | 8 | 0.150 |
Why?
|
| Host-Parasite Interactions | 1 | 2017 | 43 | 0.150 |
Why?
|
| Helminth Proteins | 1 | 2017 | 24 | 0.150 |
Why?
|
| Rats, Long-Evans | 1 | 2015 | 86 | 0.140 |
Why?
|
| Female | 7 | 2016 | 19873 | 0.140 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 11 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2005 | 25 | 0.130 |
Why?
|
| Cisplatin | 1 | 2013 | 70 | 0.120 |
Why?
|
| Receptors, Histamine | 1 | 2013 | 3 | 0.120 |
Why?
|
| Histamine Antagonists | 1 | 2013 | 6 | 0.110 |
Why?
|
| Job Application | 1 | 2012 | 3 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2012 | 30 | 0.110 |
Why?
|
| Professional Competence | 1 | 2012 | 34 | 0.110 |
Why?
|
| Staff Development | 1 | 2012 | 28 | 0.110 |
Why?
|
| Writing | 1 | 2012 | 33 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2005 | 226 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 69 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2015 | 1442 | 0.100 |
Why?
|
| Minority Health | 1 | 2011 | 81 | 0.100 |
Why?
|
| Communication | 1 | 2012 | 170 | 0.100 |
Why?
|
| Students | 1 | 2015 | 452 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 180 | 0.100 |
Why?
|
| Nanocapsules | 1 | 2010 | 16 | 0.100 |
Why?
|
| Male | 4 | 2015 | 18870 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2010 | 150 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 152 | 0.090 |
Why?
|
| Education, Medical | 1 | 2010 | 97 | 0.090 |
Why?
|
| Aged | 3 | 2005 | 6448 | 0.080 |
Why?
|
| Insulin | 1 | 2010 | 224 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 2333 | 0.080 |
Why?
|
| Risk Factors | 2 | 2008 | 3414 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 446 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 756 | 0.070 |
Why?
|
| Animals | 4 | 2017 | 14307 | 0.070 |
Why?
|
| Middle Aged | 3 | 2005 | 9642 | 0.070 |
Why?
|
| Life Style | 1 | 2008 | 288 | 0.070 |
Why?
|
| Prognosis | 1 | 2008 | 707 | 0.070 |
Why?
|
| Smad4 Protein | 1 | 2005 | 6 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 269 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2003 | 11 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 430 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 183 | 0.060 |
Why?
|
| Demography | 1 | 2003 | 167 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 70 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 859 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 133 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 78 | 0.050 |
Why?
|
| Rats | 3 | 2017 | 3261 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 964 | 0.050 |
Why?
|
| Incidence | 1 | 2003 | 882 | 0.050 |
Why?
|
| Alcoholism | 1 | 2003 | 220 | 0.050 |
Why?
|
| Adult | 2 | 2005 | 11034 | 0.040 |
Why?
|
| Cell Survival | 2 | 2013 | 818 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2003 | 1352 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 537 | 0.040 |
Why?
|
| Echinococcus granulosus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2017 | 11 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 903 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 214 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2017 | 202 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2005 | 1802 | 0.040 |
Why?
|
| Internet | 1 | 2015 | 204 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 612 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 751 | 0.030 |
Why?
|
| Betahistine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Reflex, Vestibulo-Ocular | 1 | 2013 | 1 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 2013 | 4 | 0.030 |
Why?
|
| Neurons, Afferent | 1 | 2013 | 41 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 342 | 0.030 |
Why?
|
| Universities | 1 | 2015 | 363 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 1426 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2010 | 60 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 32 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 67 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 138 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 480 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 472 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2561 | 0.020 |
Why?
|